Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03623854
What this trial is testing

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Who this might be right for
ChordomaLocally Advanced ChordomaMetastatic Chordoma+1 more
Jonsson Comprehensive Cancer Center 10
Early research (Phase 1)Looking for participantsNCT05357651
What this trial is testing

Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

Who this might be right for
Solid TumorLymphoma
L & L Bio Co., Ltd., Ningbo, China 100
Not applicableUnknownNCT05701553
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 20
Testing effectiveness (Phase 2)Study completedNCT04172454
What this trial is testing

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMelanoma
Akeso 68
Testing effectiveness (Phase 2)Study completedNCT04870177
What this trial is testing

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Who this might be right for
Gynecologic CancerCancer MetastaticOvarian Neoplasms+2 more
Akeso 53
Testing effectiveness (Phase 2)UnknownNCT05307198
What this trial is testing

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

Who this might be right for
Rectal Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05747716
What this trial is testing

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Who this might be right for
Metastatic Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 44
Testing effectiveness (Phase 2)UnknownNCT05461235
What this trial is testing

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Who this might be right for
PD-1 AntibodyDC-CellNK-Cell+1 more
China Medical University, China 1
Testing effectiveness (Phase 2)Study completedNCT03432598
What this trial is testing

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

Who this might be right for
Locally Advanced Lung Cancer; Metastatic Lung Cancer
BeiGene 54
Not applicableNot Yet RecruitingNCT07438093
What this trial is testing

Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
The First Affiliated Hospital of Xiamen University 60
Testing effectiveness (Phase 2)UnknownNCT04976647
What this trial is testing

HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Who this might be right for
Squamous Non-small-cell Lung Cancer
Shanghai Henlius Biotech 156
Testing effectiveness (Phase 2)Looking for participantsNCT06364384
What this trial is testing

Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma

Who this might be right for
Rectal Squamous Cell Carcinoma
Sixth Affiliated Hospital, Sun Yat-sen University 20
Early research (Phase 1)Ended earlyNCT03425461
What this trial is testing

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Who this might be right for
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7+3 more
Jonsson Comprehensive Cancer Center 6
Early research (Phase 1)UnknownNCT05095441
What this trial is testing

A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

Who this might be right for
Solid TumorGlioblastomaGlioblastoma Multiforme+1 more
ImmVira Pharma Co. Ltd 51
Large-scale testing (Phase 3)Not Yet RecruitingNCT07739186
What this trial is testing

A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT06508606
What this trial is testing

AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
West China Hospital 20
Early research (Phase 1)Study completedNCT03708328
What this trial is testing

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Who this might be right for
Solid TumorsMetastatic MelanomaNon-small Cell Lung Cancer (NSCLC)+2 more
Hoffmann-La Roche 134
Early research (Phase 1)UnknownNCT04280341
What this trial is testing

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

Who this might be right for
HER2-Positive Solid Tumors
Peking University 50
Early research (Phase 1)Study completedNCT01176474
What this trial is testing

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Who this might be right for
Melanoma (Skin)
H. Lee Moffitt Cancer Center and Research Institute 73
Early research (Phase 1)Study completedNCT02966548
What this trial is testing

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Who this might be right for
Cancer
Bristol-Myers Squibb 35
Next Page